Merck & Co. Inc. expects the company’ immunotherapy Keytruda will continue the drug’s market dominance as an initial treatment for advanced lung cancer as sales of the medicine topped $3 billion in a quarter for the first time, beating lofty Wall Street estimates.
Gilead Sciences Inc. reported third-quarter results largely in line with Wall Street estimates, led by higher sales of the company’s HIV drugs, but deal-related costs led to a net loss.
Eli Lilly third-quarter 2019 sales missed Wall Street estimates as rebates limited revenue from the drug manufacturer’s top-selling diabetes medicine Trulicity, and shares fell about 4 percent.
Amgen Inc.’s second-quarter revenue fell 3 percent due to more competition for the company’s older off-patent drugs, but rising sales of newer medicines helped the biotechnology innovator’s results exceed Wall Street forecasts.
Gilead Sciences Inc. beat Wall Street estimates for second-quarter 2019 revenue and profit, driven by higher sales of HIV treatments, and the U.S. drugmaker raised the company’s full-year sales forecast.
Biogen Inc. reported better-than-expected second quarter 2019 profit and raised the company’s full-year earnings forecast, driven by higher sales of the top-selling multiple sclerosis drug Tecfidera and lower taxes.
